Syncona Portfolio Ltd - Q1 2023 holdings

$61.5 Million is the total value of Syncona Portfolio Ltd's 4 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .

 Value Shares↓ Weighting
AUTL  AUTOLUS THERAPEUTICS PLCspon ads$39,278,165
-3.2%
21,346,8290.0%63.85%
-0.8%
ACHL  ACHILLES THERAPEUTICS PLCsponsored ads$10,615,715
+6.4%
11,086,9090.0%17.26%
+9.0%
FRLN  FREELINE THERAPEUTICS HLDGSsponsored ads$10,118,905
-3.2%
21,997,6200.0%16.45%
-0.8%
ADAP  ADAPTIMMUNE THERAPEUTICS PLCsponds adr$1,501,250
-25.3%
1,377,2940.0%2.44%
-23.6%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Syncona Holdings Limited #1
  • Syncona Limited #2
  • Syncona Investment Management Limited #3
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AUTOLUS THERAPEUTICS PLC8Q3 202376.6%
ACHILLES THERAPEUTICS PLC8Q3 202353.1%
FREELINE THERAPEUTICS HLDGS8Q3 202327.4%
ADAPTIMMUNE THERAPEUTICS PLC8Q3 20234.9%

View Syncona Portfolio Ltd's complete holdings history.

Latest significant ownerships (13-D/G)
Syncona Portfolio Ltd Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Freeline Therapeutics Holdings plcMarch 25, 202237,862,14762.3%
Nightstar Therapeutics plcMarch 14, 201913,203,92239.0%

View Syncona Portfolio Ltd's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-02-22
SC 13G/A2024-02-13
SC 13G/A2024-02-13
13F-HR2024-02-01
SC 13D/A2023-11-24
13F-HR2023-11-01
SC 13D/A2023-10-18
13F-HR2023-07-27
13F-HR2023-05-12
SC 13G/A2023-02-14

View Syncona Portfolio Ltd's complete filings history.

Compare quarters

Export Syncona Portfolio Ltd's holdings